Skip to main content
. 2021 Jan 8;10:585551. doi: 10.3389/fonc.2020.585551

Figure 1.

Figure 1

RAD51 overexpression links MYBL2 with genomic instability in BRCA wildtype lung adenocarcinoma. (A) Kaplan-Meier analyses reveal that patients with RAD51 High tumors have significantly worse OS outcomes, compared to patients with RAD51 Low tumors (log-rank p = 6.03e–4, ΔMMS = 18.79 months). (B) Kaplan-Meier analyses reveal that RAD51 High tumors are more likely to recur, compared to RAD51 Low tumors (log-rank p = 1.48e–2, ΔMMS = 17.08 months). (C) RAD51 High tumors (N = 122) exhibit elevated Combined HRD scores, compared to RAD51 Low (N = 121) (T-test, two-sided) (20). Boxplot data is displayed as a five-number summary corresponding to data minimum, first quartile, median, third quartile, and maximum. (D) Oncoprint profiling reveals BRCA1 and BRCA2 mutations are rare in both RAD51 High (N = 46) and RAD51 Low (N = 58) cohorts (27). (E) MYBL2 is the most differentially expressed transcription factor upregulated in RAD51 High tumors (Log Ratio = 3.64, q = 1.68e–74) (28).